Search
Displaying 51–60 of 1180 results
-
Stargardt Disease Research Advances
Research NewsRecent developments in research on Stargardt disease.
-
Finding the Light Within: How Joslyn Turned Vision Loss into Purpose
Beacon StoriesJoslyn Marquez spent years searching for answers before being diagnosed with retinitis pigmentosa at the age of 16. Rather than allowing vision loss to define her, she transformed her journey into a source of purpose, community and empowerment.
-
Foundation News
The new name honors the decades of leadership and giving by Foundation co-founder Gordon Gund and his family, honoring the Fund’s evolution into one of the most innovative venture philanthropy models in the retinal disease market.
-
The following list of doctors has been compiled by the Foundation Fighting Blindness for the convenience of patients and families. The accuracy of the list cannot be guaranteed nor should it be construed as an endorsement of any doctor.
-
Eye on the Cure Podcast | Episode 103: Kenyetta McCurdy-Byrd and Heather Edwards
Eye on the CureTwo non-profit professionals talk about plugging into community and finding low-vision resources through the Foundation.
-
First patient treated with potential retinitis pigmentosa treatment from Sumitomo Pharma America
Research NewsCell therapy DSP-3077 is in Phase 1/2a clinical trials
-
Tarsus plans to purchase Alkeus, developer of emerging Stargardt treatment
Research NewsDeal marks another step as gildeuretinol advances towards patients
-
Jackson's New Discoveries After LUXTURNA
Beacon StoriesAfter receiving LUXTURNA at age 9, Jackson Kennedy began experiencing everyday moments he had never been able to see before—from ice cubes floating in a glass to traffic moving through a city street. Today, Jackson is an honor roll student and dedicated wrestler looking ahead to college, while embracing the possibilities his treatment has helped make possible.
-
PRIMA retinal implant restores sight in patients with geographic atrophy from AMD
Research NewsProduct launched in Europe, U.S. approval in progress
